Signals, Powered By EquityPandit
Morepen Laboratories has received approval for its Baddi facility at Himachal Pradesh, from USFDA.
The company’s Baddi facility has received approval for the manufacture of bulk drug Atorvastatin Calcium, a Cholesterol reducing drug, and its Masulkhana facility has recently received approval for manufacturing an anti-asthma bulk drug Montelukast Sodium, for export to the US market.
Further, Sushil Suri, Chairman and MD of Morepen Laboratories stated, “With this development in place, the company is set to expand its foothold in the combined Rs.7,000 crore US market for Atorvastatin and Montelukast. The two APIs will also strengthen company’s existing APIs portfolio comprising Loratadine and Desloratadine in the US market.”
